223 related articles for article (PubMed ID: 24677018)
1. An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Darwish M; Burke JM; Hellriegel E; Robertson P; Phillips L; Ludwig E; Munteanu MC; Bond M
Cancer Chemother Pharmacol; 2014 Jun; 73(6):1119-27. PubMed ID: 24677018
[TBL] [Abstract][Full Text] [Related]
2. Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma.
Burke JM; van der Jagt RH; Flinn IW; Craig MD; Chen L; Morganroth J; Munteanu MC; MacDonald DA
Cancer Chemother Pharmacol; 2015 Jul; 76(1):211-6. PubMed ID: 26006703
[TBL] [Abstract][Full Text] [Related]
3. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG).
Weide R; Hess G; Köppler H; Heymanns J; Thomalla J; Aldaoud A; Losem C; Schmitz S; Haak U; Huber C; Unterhalt M; Hiddemann W; Dreyling M;
Leuk Lymphoma; 2007 Jul; 48(7):1299-306. PubMed ID: 17613757
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.
Rummel MJ; Niederle N; Maschmeyer G; Banat GA; von Grünhagen U; Losem C; Kofahl-Krause D; Heil G; Welslau M; Balser C; Kaiser U; Weidmann E; Dürk H; Ballo H; Stauch M; Roller F; Barth J; Hoelzer D; Hinke A; Brugger W;
Lancet; 2013 Apr; 381(9873):1203-10. PubMed ID: 23433739
[TBL] [Abstract][Full Text] [Related]
5. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
6. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma.
Friedberg JW; Vose JM; Kelly JL; Young F; Bernstein SH; Peterson D; Rich L; Blumel S; Proia NK; Liesveld J; Fisher RI; Armitage JO; Grant S; Leonard JP
Blood; 2011 Mar; 117(10):2807-12. PubMed ID: 21239695
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine: a review of its use in the management of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Garnock-Jones KP
Drugs; 2010 Sep; 70(13):1703-18. PubMed ID: 20731477
[TBL] [Abstract][Full Text] [Related]
8. Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma.
Ogura M; Ando K; Taniwaki M; Watanabe T; Uchida T; Ohmachi K; Matsumoto Y; Tobinai K;
Cancer Sci; 2011 Sep; 102(9):1687-92. PubMed ID: 21624007
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.
Flinn IW; van der Jagt R; Kahl BS; Wood P; Hawkins TE; Macdonald D; Hertzberg M; Kwan YL; Simpson D; Craig M; Kolibaba K; Issa S; Clementi R; Hallman DM; Munteanu M; Chen L; Burke JM
Blood; 2014 May; 123(19):2944-52. PubMed ID: 24591201
[TBL] [Abstract][Full Text] [Related]
10. Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management.
Brugger W; Ghielmini M
Oncologist; 2013; 18(8):954-64. PubMed ID: 23900001
[TBL] [Abstract][Full Text] [Related]
11. Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.
Gopal AK; Tarantolo SR; Bellam N; Green DJ; Griffin M; Feldman T; Mato AR; Eisenfeld AJ; Stromatt SC; Goy A
Invest New Drugs; 2014 Dec; 32(6):1213-25. PubMed ID: 24927856
[TBL] [Abstract][Full Text] [Related]
12. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
Munakata W; Tobinai K
Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
[TBL] [Abstract][Full Text] [Related]
13. Bendamustine: a review of its use in the management of indolent non-Hodgkin lymphoma.
Plosker GL; Carter NJ
Drugs; 2008; 68(18):2645-60. PubMed ID: 19093705
[TBL] [Abstract][Full Text] [Related]
14. Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial.
Rummel M; Kaiser U; Balser C; Stauch M; Brugger W; Welslau M; Niederle N; Losem C; Boeck HP; Weidmann E; von Gruenhagen U; Mueller L; Sandherr M; Hahn L; Vereshchagina J; Kauff F; Blau W; Hinke A; Barth J;
Lancet Oncol; 2016 Jan; 17(1):57-66. PubMed ID: 26655425
[TBL] [Abstract][Full Text] [Related]
15. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
[TBL] [Abstract][Full Text] [Related]
16. Routine use of bendamustine and rituximab combination therapy in consecutive patients with lymphoproliferative diseases: a survey from Tyrolean hospitals.
Waldthaler C; Stauder R; Schnallinger M; Schreieck S; Hager J; Oexle H; Zangerl G; Verdorfer I; Zabernigg A; Gastl G; Fiegl M
Wien Klin Wochenschr; 2011 May; 123(9-10):269-75. PubMed ID: 21479652
[TBL] [Abstract][Full Text] [Related]
17. Navitoclax (ABT-263) and bendamustine ± rituximab induce enhanced killing of non-Hodgkin's lymphoma tumours in vivo.
Ackler S; Mitten MJ; Chen J; Clarin J; Foster K; Jin S; Phillips DC; Schlessinger S; Wang B; Leverson JD; Boghaert ER
Br J Pharmacol; 2012 Oct; 167(4):881-91. PubMed ID: 22624727
[TBL] [Abstract][Full Text] [Related]
18. Bendamustine in the treatment of non-Hodgkin's lymphoma: results and future perspectives.
Rummel MJ; Mitrou PS; Hoelzer D
Semin Oncol; 2002 Aug; 29(4 Suppl 13):27-32. PubMed ID: 12170430
[TBL] [Abstract][Full Text] [Related]
19. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
Maddocks K; Christian B; Jaglowski S; Flynn J; Jones JA; Porcu P; Wei L; Jenkins C; Lozanski G; Byrd JC; Blum KA
Blood; 2015 Jan; 125(2):242-8. PubMed ID: 25355819
[TBL] [Abstract][Full Text] [Related]
20. Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma.
Burke JM; van der Jagt RH; Kahl BS; Wood P; Hawkins TE; MacDonald D; Hertzberg M; Simpson D; Craig M; Kolibaba K; Issa S; Munteanu M; Victor TW; Flinn IW
Clin Lymphoma Myeloma Leuk; 2016 Apr; 16(4):182-190.e1. PubMed ID: 26875824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
